UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 117

Sortiert nach

Does combination of "cold" and "hot" somatostatin analogs prolong survival of patients with neuroendocrine neoplasms?

ENDOCRINE JOURNAL, 2017-02, Vol.64 (2), p.171-177

2017

Link zum Volltext

Verfügbarkeit prüfen

Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma

European journal of nuclear medicine and molecular imaging, 2013-04, Vol.40 (4), p.524-531

2013

Link zum Volltext

Verfügbarkeit prüfen

Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)

European journal of nuclear medicine and molecular imaging, 2011-09, Vol.38 (9), p.1669-1674

2011

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of Selected Single-Nucleotide Variants in Patients with Neuroendocrine Tumors—Potential Clinical Relevance

Journal of clinical medicine, 2022-09, Vol.11 (19), p.5536

2022

Link zum Volltext

Verfügbarkeit prüfen

99mTc Labeled Glucagon-Like Peptide-1-Analogue (99mTc-GLP1) Scintigraphy in the Management of Patients with Occult Insulinoma

PloS one, 2016-08, Vol.11 (8), p.e0160714-e0160714

2016

Link zum Volltext

Verfügbarkeit prüfen

Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center

Polskie archiwum medycyny wewne̦trznej, 2015-01, Vol.125 (5), p.337-346

2015

Link zum Volltext

Verfügbarkeit prüfen

NEN - the role of somatostatin receptor scintigraphy in clinical setting

Nuclear medicine review. Central & Eastern Europe, 2016-01, Vol.19 (2), p.118-125

2016

Link zum Volltext

Verfügbarkeit prüfen

sup.99mTc Labeled Glucagon-Like Peptide-1-Analogue Scintigraphy in the Management of Patients with Occult Insulinoma

PloS one, 2016-08, Vol.11 (8), p.e0160714

2016

Link zum Volltext

Verfügbarkeit prüfen

Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors?

Clinical imaging, 2012-07, Vol.36 (4), p.360-364

2012

Link zum Volltext

Verfügbarkeit prüfen

Case report of a patient with initially inoperable well-differentiated midgut neuroendocrine tumor (WDNT)--PRRT and long-acting somatostatin analogs as the neoadjuvant therapy

Nuclear medicine review. Central & Eastern Europe, 2012-01, Vol.15 (2), p.137-139

2012

Link zum Volltext

Verfügbarkeit prüfen

Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with non-functioning neuroendocrine pancreatic tumours?

Nuclear medicine review. Central & Eastern Europe, 2011-01, Vol.14 (2), p.73-78

2011

Link zum Volltext

Verfügbarkeit prüfen

P10-5-6 Side-effects and response to the radioisotope 90Y/177Lu DOTA-TATE therapy in patients with disseminated NET-Do repeated cycles of PRRT increase toxicity of the therapy?

ENDOCRINE JOURNAL, 2010, Vol.57 (suppl.2-2), p.S587-S587

2010

Link zum Volltext

Verfügbarkeit prüfen

P3-1-8 Assessment of somatostatin receptor expression in predicting results of PRRT(peptide receptor radionuclide therapy)in disseminated neuroendocrine tumours(NET)

ENDOCRINE JOURNAL, 2010, Vol.57 (suppl.2-2), p.S443-S443

2010

Link zum Volltext

Verfügbarkeit prüfen

O15-2 Case report of a patient with two independent well-differentiated midgut neuroendocrine tumors(WDNT)-diagnostic doubts and treatment options

ENDOCRINE JOURNAL, 2010, Vol.57 (suppl.2-1), p.S348-S348

2010

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of ⁹⁰Y-DOTATATE therapy in neuroendocrine tumours

Endokrynologia polska, 2011-01, Vol.62 (5), p.392-400

2011

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours

Endokrynologia Polska, 2011, Vol.62 (5), p.392

2011

Link zum Volltext

Verfügbarkeit prüfen

Epidemiologia nowotworów neuroendokrynnych układu pokarmowego w Krakowie i powiecie krakowskim w latach 2007-2011

Endokrynologia polska, 2017-03, Vol.68 (1), p.42-46

2017

Link zum Volltext

Verfügbarkeit prüfen

MON-584 Iodine Nutrition Status in Pregnancy: Is the Situation in Poland Improving?

Journal of the Endocrine Society, 2019-04, Vol.3 (Supplement_1)

2019

Link zum Volltext

Verfügbarkeit prüfen

Repeated cycles of peptide receptor radionuclide therapy (PRRT) – Results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET

Radiotherapy and oncology, 2012-01, Vol.102 (1), p.45-50

2012

Link zum Volltext

Verfügbarkeit prüfen

Repeated cycles of peptide receptor radionuclide therapy (PRRT) – Results and side-effects of the radioisotope90 Y-DOTA TATE,177 Lu-DOTA TATE or90 Y/177 Lu-DOTA TATE therapy in patients with disseminated NET

Radiotherapy and oncology, 2011, Vol.102 (1), p.45-50

2011

Link zum Volltext

Verfügbarkeit prüfen

LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors - results of interim analysis

Contemporary oncology (Poznań, Poland), 2014-01, Vol.18 (6), p.442-447

2014

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of radioiodine 131I treatment in Graves' disease patients with mild orbitopathy

Przeglad lekarski, 2009, Vol.66 (4), p.166

2009

Link zum Volltext

Verfügbarkeit prüfen

Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients – results from the prospective 12-month phase of Lanro-Study

Contemporary oncology (Poznań, Poland), 2013, Vol.17 (5), p.460-465

2013

Link zum Volltext

Verfügbarkeit prüfen

Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients - results from the prospective 12-months phase of Lanro-Study

Contemporary oncology (Poznań, Poland), 2013-09, Vol.17 (5), p.460

2013

Link zum Volltext

Verfügbarkeit prüfen

New forms of radionuclide therapy with (90)Y in oncology

Nuclear medicine review. Central & Eastern Europe, 2008, Vol.11 (1), p.5

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 117

Suche als RSS-Feed

Aktive Filter

KollektioneBooks on EBSCOhost

ThemaEndocrinology & Metabolism

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(114)
Mit Volltextzugriff
(106)

Publikationsform

Artikel
(117)

Sprache

Englisch
(106)
Polnisch
(16)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Does combination of "cold" and "hot" somatostatin analogs prolong survival of patients with neuroendocrine neoplasms?

Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma

Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)

Prevalence of Selected Single-Nucleotide Variants in Patients with Neuroendocrine Tumors—Potential Clinical Relevance

99mTc Labeled Glucagon-Like Peptide-1-Analogue (99mTc-GLP1) Scintigraphy in the Management of Patients with Occult Insulinoma

Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center

NEN - the role of somatostatin receptor scintigraphy in clinical setting

sup.99mTc Labeled Glucagon-Like Peptide-1-Analogue Scintigraphy in the Management of Patients with Occult Insulinoma

Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors?

Case report of a patient with initially inoperable well-differentiated midgut neuroendocrine tumor (WDNT)--PRRT and long-acting somatostatin analogs as the neoadjuvant therapy

Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with non-functioning neuroendocrine pancreatic tumours?

P10-5-6 Side-effects and response to the radioisotope 90Y/177Lu DOTA-TATE therapy in patients with disseminated NET-Do repeated cycles of PRRT increase toxicity of the therapy?

P3-1-8 Assessment of somatostatin receptor expression in predicting results of PRRT(peptide receptor radionuclide therapy)in disseminated neuroendocrine tumours(NET)

O15-2 Case report of a patient with two independent well-differentiated midgut neuroendocrine tumors(WDNT)-diagnostic doubts and treatment options

Efficacy and safety of ⁹⁰Y-DOTATATE therapy in neuroendocrine tumours

Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours

Epidemiologia nowotworów neuroendokrynnych układu pokarmowego w Krakowie i powiecie krakowskim w latach 2007-2011

MON-584 Iodine Nutrition Status in Pregnancy: Is the Situation in Poland Improving?

Repeated cycles of peptide receptor radionuclide therapy (PRRT) – Results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET

Repeated cycles of peptide receptor radionuclide therapy (PRRT) – Results and side-effects of the radioisotope90 Y-DOTA TATE,177 Lu-DOTA TATE or90 Y/177 Lu-DOTA TATE therapy in patients with disseminated NET

LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors - results of interim analysis

Evaluation of radioiodine 131I treatment in Graves' disease patients with mild orbitopathy

Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients – results from the prospective 12-month phase of Lanro-Study

Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients - results from the prospective 12-months phase of Lanro-Study

New forms of radionuclide therapy with (90)Y in oncology

Aktive Filter

Suchergebnisse filtern